This brings us to the end of the first episode of Gilead’s viral hepatitis elimination webinar series. This episode covered innovative strategies for reach communities of people who inject drugs, and the critical importance of providing integrated harm reduction services in eliminating viral hepatitis.
Join Shanell McCoy and Amy O’Brien from Gilead’s Corporate Giving team as they give closing remarks on the Harm Reduction episode.
For more information on the grantees included in this episode, visit:
Community Education Group: communityeduca...
HCSA Singapore: hcsa.org.sg/
Villa Maraini: villamaraini.it/
Community Liver Alliance: communityliver...
For more information about Gilead, visit:
Website: www.gilead.com
Stories@Gilead: stories.gilead...
Twitter: / gileadsciences
LinkedIn: / gileadsc. .
Instagram: / gileadsciences
Facebook: / gileadsciences
About Gilead
Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.
This webinar episode was created and fully funded by Gilead Sciences, Inc. GILEAD, the GILEAD logo, and the & design are trademarks of Gilead Sciences, Inc. © 2023 Gilead Sciences, Inc. All rights reserved.
8 ноя 2023
